Microfluidic Assisted Nanoprecipitation of PLGA Nanoparticles for Curcumin Delivery to Leukemia Jurkat Cells by Mandy H. M. Leung & Amy Q. Shen
Microfluidic Assisted Nanoprecipitation of
PLGA Nanoparticles for Curcumin Delivery to
Leukemia Jurkat Cells
Author Mandy H. M. Leung, Amy Q. Shen
journal or
publication title
Langmuir
volume 34
number 13
page range 3961-3970
year 2018-03-15
Publisher American Chemical Society
Rights (C) 2018 American Chemical Society
This document is the Accepted Manuscript
version of a Published Work that appeared in
final form in Langmuir, copyright (C) American
Chemical Society after peer review and
technical editing by the publisher. To access
the final edited and published work see
https://pubs.acs.org/doi/10.1021/acs.langmuir.
7b04335 or ACS Articles on Request,
https://pubs.acs.org/page/4authors/benefits/in
dex.html#articles-request. 
Author's flagauthor
URL http://id.nii.ac.jp/1394/00000684/
doi: info:doi/10.1021/acs.langmuir.7b04335
Microfluidic Assisted Nanoprecipitation of
PLGA Nanoparticles for Curcumin Delivery to
Leukemia Jurkat Cells
Mandy H. M. Leung and Amy Q. Shen∗
Micro/Bio/Nanofluidics Unit, Okinawa Institute of Science and Technology Graduate
University, 1919-1 Tancha, Onna-son, Kunigami-gun, Okinawa, 904-0495 Japan
E-mail: amy.shen@oist.jp
Phone: +81-(0)98-982-3374. Fax: +81-98-982-3420
Abstract
The ability to control particle size and size distribution of nanoparticles for drug
delivery is essential because it impacts on the biodistribution and cellular uptake of
nanoparticles. We present a novel microfluidic assisted nanoprecipitation strategy that
enables synthesis of surfactant-free curcumin encapsulated poly(lactide-co-glycolide)
nanoparticles (Cur-PLGA NP) with adjustable particle diameters (30–70 nm) and nar-
row particle size distribution (polydispersity index less than 0.2). Our Cur-PLGA NP
exhibit excellent colloidal stability and inhibit degradation of curcumin. We further
demonstrate the potential of our Cur-PLGA NP as a nanotoxic delivery system for cur-
cumin. Cellular viability assay validates a dose-dependent cytotoxicity of Cur-PLGA
NP in leukemia Jurkat cells. In contrast, Cur-PLGA NP does not alter the viability
of fibroblast NIH3T3 cells, which suggests that the cytotoxicity of Cur-PLGA NP is
specific to cell types. Furthermore, there is no detectable effect by PLGA NP to both
leukemia Jurkat cells and fibroblast NIH3T3 cells, highlighting the nontoxic nature of
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our delivery system. Confocal cell uptake studies indicate that PLGA NP do not alter
the cell uptake of curcumin. Our microfluidic assisted approach offers a controlled and
effective nano-biomaterials synthesis of drug delivery system for curcumin, which can
be extended to different capsule materials for a variety of biomedical applications.
INTRODUCTION
Amongst all the FDA-approved biodegradable polymers, poly(lactide-co-glycolide) (PLGA,
Figure 1a) has demonstrated immense potential as a drug delivery carrier due to its excel-
lent biocompatibility and biodegradability.1–3 It has been shown that PLGA nanoparticles
(PLGA NP) are biocompatible, which are hydrolyzed into smaller units and further de-
graded by cells.4,5 It has been validated that PLGA NP is useful in encapsulating curcumin
to enhance its aqueous solubility and stability.1–3,6–8 Curcumin (Figure 1a), the yellow pig-
ment found in turmeric, exhibits various medicinal properties, including anti-cancer, anti-
Alzheimer’s and anti-inflammatory activities.1–3,9–12 However, the poor aqueous solubility
and the instability of curcumin hinder its bioavailability. Curcumin has a solubility of only
10 µgmL−1 in water due to its hydrophobicity but its solubility increases in polar organic
solvents.13,14 Also, the hydrolysis of curcumin has been linked to its degradation mechanism
with 50% of curcumin degraded within 30min in a pH 7.4 phosphate buffer solution.15,16
Recently, PLGA NP have been employed to deliver curcumin efficiently into cancer cells,1–3
with curcumin effectively inhibiting cancer cell proliferation.2 This anti-proliferation effect
has been linked to alteration of the cell cycle by curcumin, which reduces the S phase and
blocks the G2/M phase.2 In addition, curcumin-PLGA nanoformulation induces apoptosis
by inhibiting NFκB activation.2,17 Therefore, PLGA NP are effective delivery agents for
curcumin and they do not alter curcumin’s medicinal effect.
A previous study has shown that curcumin encapsulated PLGA NP (Cur-PLGA NP) can
be synthesized using a stabilizer-free one-step nanoprecipitation method.6 The stabilizer-free
nanoprecipitation provides a simple system for direct study of the PLGA NP without any
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Figure 1: (a) Chemical structure of curcumin and poly(D,L-lactide-co-glycolide) (PLGA).
(b) Mechanism of Cur-PLGA NP nanoprecipitation by solvent exchange. (c) Schematic of
nanoprecipitation by hydrodynamic flow focusing in a cross slot microfluidic device.
biases in nanoparticle sizing and eliminates any additional effects may have on cells by the
stabilizers.6,18,19 Stable Cur-PLGA NP of approximately 100 nm in diameter were formed by
nanoprecipitation because the solubility of curcumin and PLGA decreases upon exchange
of acetone by water.6 Nanoprecipitation via solvent exchange requires two miscible solvents,
with both PLGA and curcumin being dissolved in one system (the solvent), but not in the
other (the non-solvent). Nanoprecipitation involves three stages: nucleation, growth and
formation of stable particles as illustrated in Figure 1b.20 First, nucleation occurs when
the solution has passed supersaturation due to rapid diffusion of the solvent into the non-
solvent phase. Second, particle growth occurs upon collision, which is governed by diffusion of
curcumin and PLGA molecules. Finally, an equilibrium is reached as particles are kinetically
stable when the energy barrier for aggregation is too high. Homogeneous supersaturation,
which requires that the mixing of the solvent and the non-solvent phases, is very critical
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for formation of small particles because rapid mixing results in a high nucleation rates and
formation of smaller nuclei.20 In another word, the mixing time of the solvent and the non-
solvent phases must be less than the time scale for nanoparticle aggregation in order to
achieve small particles.21
It is well established that nanoparticles accumulate in tumors due to enhanced perme-
ability and retention (EPR) of defective vessels and inefficient lymphatic drainage, one of the
underlying mechanisms to deliver drugs encapsulated in nanoparticles.22,23 Particle size is
critical for EPR effect as particles with size less than 10 nm are easily cleared by the kidneys
and the pore cut-off size of blood vessels is about 100 nm.22,23 Therefore, particles between
10 nm and 100 nm can be passively accumulated in tumors by EPR. It has been suggested
that the slow and uncontrolled mixing of solvent in a typical nanoprecipitation synthesis
is responsible for the formation of larger nanoparticles with a wide particle size distribu-
tion.20,21 Previous stabilizer-free one-step nanoprecipitation method gives Cur-PLGA NP of
approximately 100 nm in diameter with a particle size distribution across 20 to 120 nm.6
In response to this challenge, microfluidic reactor has emerged as a powerful platform to
provide rapid and controlled mixing of solutions, which decreases the mixing time, leading
to formation of smaller nanoparticles with a narrower size distribution compared to those
from traditional nanoprecipitation methods.21,24–26
The primary aim of this work is to synthesize surfactant-free Cur-PLGA NP with particle
diameters less than 100 nm and a narrow size distribution to achieve the EPR effect, by
using controlled nanoprecipitation with a microfluidic platform. Figure 1c illustrates the
nanoprecipitation of Cur-PLGA NP using hydrodynamic flow focusing inside a cross slot
microfluidic device. The microfluidic synthesized PLGA NP not only exhibit a suppression
of curcumin degradation, but also act as an efficient delivery agent for curcumin. The anti-
cancer effect of the synthesized Cur-PLGA NP is also evaluated by using luekemia Jurkat
cells and NIH3T3 fibroblast cells for in vitro studies. The in vitro cell studies demonstrate
that the microfluidic synthesized PLGA NP has great potential as a drug delivery system
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for curcumin.
EXPERIMENTAL SECTION
Materials
Curcumin (purity >98%) and poly(D,L-lactide-co-glycolide) (PLGA, acid terminated, 50:50
lactide:glycolide, Mw: 24 000 to 38 000) were purchased from Sigma Aldrich (Japan). Ace-
tone and triethylamine from Nacalai (Japan) and ethyl acetate from Wako (Japan) were
used as received. Water from a Millipore Milli-Q NANOpure water system was used in all
experiments. Leukemia Bcl-2 (S70A) Jurkat and NIH3T3 (mouse embryonic fibroblast) cell
lines are from ATCC (USA). RPMI 1640 media and Dulbecco’s modified Eagle medium
(DMEM) were purchased from Invitrogen (USA). Jurkat cells were grown in RPMI 1640
media containing 10% fetal bovine serum. NIH3T3 cells were grown in DMEM containing
10% iron fortified calf serum. All media contain 1% geneticin. Cells were cultured at 37 ◦C
in a humidified atmosphere of 5% CO2.
Microfluidic device fabrication
The microfluidic devices were fabricated using soft lithography.27 In brief, the cross slot
microfluidic device (Figure 1c) with channel width of 20 µm were designed with AutoCAD
(AutoDesk, USA). A layer of DWL 40 photoresist with a thickness of 60 µm was coated
onto a 4-inch in diameter silicon wafer. The features of the cross slot microfluidic device
were patterned by photolithgraphy using a DL1000 maskless writer (NanoSystem Solutions,
Japan) and developed by using a mr-Dev 600 developer (Microresist Technologies, Ger-
many). The wafer was subsequently coated with an anti-adhesive layer by exposing it to
trichloro(1H,1H,2H,2H -perfluorooctyl)silane (Sigma Aldrich, Japan) in the vapor phase in a
desiccator for at least 1 h. A mixture of 10:1 poly-(dimethylsiloxane) (PDMS) (Sylgard 184,
Dow Corning, Japan) was poured onto the wafer, desiccated and cured for 24 h at 60 ◦C.
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The resulting PDMS cast was peeled off from the wafer, and extracted in the order of tri-
ethylamine, ethyl acetate and acetone for 2 h, respectively, to remove the uncross-linked low
molecular weight oligomers.28 The extracted PDMS piece was then dried in a 60 ◦C oven
overnight, followed by air plasma (80 s) bonded onto a glass-slide using a plasma cleaner
(Harrick Plasma, USA). The assembled device was then heated at 80 ◦C for 2 h on a hot
plate to strengthen the bonding of the PDMS slab to the glass substrate. The microfluidic
device contains one outlet and one inlet for each continuous and dispersed phase, while the
inlet for the continuous phase was split into two streams at the flow focusing junction.
Cur-PLGA NP synthesis
A stock solution of curcumin and PLGA in acetone was introduced into the device as dis-
persed phase through the inserted PTFE tubing (OD: 1/16" and ID: 1/32", OMNIFIT
tubing). Syringe pumps (YSP-101 from YMC, Japan) mounted with gas-tight glass syringes
were used to control the flow rate of the continuous (SGE Analytical Science, Australia) and
dispersed phases (Hamilton, USA). The acetone was then removed under reduced pressure
at 40 ◦C until the volume of the collected Cur-PLGA NP solution was reduced approximately
by half to ensure complete removal of acetone. The resulting Cur-PLGA NP solution was
kept refrigerated and filtered with a 200 nm syringe-driven filter (Millex from Merck, Ger-
many) to ensure that there is no large aggregates in the sample before testing. The resulting
Cur-PLGA solution was kept in the dark environment to limit the exposure to ambient light.
The in situ nanoprecipitation at the cross slot was imaged using spinning disk and structured
illumination hybrid fluorescent confocal imaging (Andor DSD2, Japan) at 20x magnification
on an inverted microscope (Ti-E, Nikon, Japan)
Cur-PLGA NP characterization
Images of the synthesized bare PLGA NP and Cur-PLGA NP were taken with Dimension
ICON3 atomic force microscope (AFM) with a NanoScope V controller (Bruker, USA).
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Nanoparticle suspension was drop-casted onto an atomically flat mica substrate and dried
under vacuum. Measurements were performed using silicon cantilevers with a resonance
frequency around 300 kHz and a typical tip radius of 7 nm (OTESPA-R3, Bruker, USA) in
tapping mode at a scan rate of 1 kHz with a spatial resolution of 256 × 256 pixel. AFM
images were processed with NanoScope Analysis (Bruker, USA) and the particle size profile
was analyzed by ImageJ for randomly selected 100 particles.29
Transmission electron microscopy (TEM) was used to investigate the morphology of bare
PLGA NP and Cur-PLGA NP. Nanoparticle suspension was drop-casted onto air plasma
activated copper grid (400 mesh) coated with carbon film and dried at ambient temperature
after removal of excess solution. To enhance contrast for imaging purposes, the sample was
then stained with 1% (w/v) uranyl acetate (UA) solution before imaging at high vacuum
with TEM (JEM-1230R, JEOL, Japan) at 300 kV.
The size distribution of synthesized nanoparticles were characterized by dynamic light
scattering (DLS). DLS experiments were performed with a 3D LS spectrometer (LS Instru-
ments, Switzerland) equipped with a HeNe laser operating at 633 nm. The measurements
were made at scattering angles ranging from 90◦ to 135◦. Samples were placed in borosilicate
cylindrical glass cuvettes (LS Instruments, Switzerland) and allowed 15-min equilibration
time at 37 ◦C prior to data acquisition. The mean hydrodynamic radius and polydispersity
index (PDI) of the nanoparticles were determined by the cumulant method.30 Particle size
distributions were determined using CONTIN analysis on the average of 10 measurements.31
Zeta potentials of the synthesized nanoparticle were measured using an electrophoretic
light scattering spectrophotometer (ELZS-2000, Otsuka Electronics Co., Ltd, Japan). Mea-
surements were taken using a disposable cell with gold-plated electrodes (Otsuka Electronics
Co., Ltd, Japan) at 37 ◦C with a 2-min equilibration time. Zeta potential was calculated
from the electrophoretic mobility using the Helmholtz-Smoluchowski equation based on the
electrophretic light scattering. Zeta potential values were reported as the mean of three
independent measurements and errors were estimated from the standard deviation.
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The encapsulation efficiency of the Cur-PLGA NP was determined by dissolving an
aliquot of a concentrated Cur-PLGA NP solution in acetone with a final volume of wa-
ter less than 5% to extract the encapsulated curcumin. The amount of curcumin presented
in Cur-PLGA NP is calculated from the absorbance of curcumin (A420 nm) of the acetone
solution measured with a UV-1800 UV-VIS spectrophotometer (Shimadzu, Japan). The
amount of curcumin present was calculated from a standard curve of absorbance at 422 nm
against the concentration of curcumin in the presence of PLGA in acetone with 1% of water
(Supporting Information Figure S.2). The curcumin encapsulation efficiency of PLGA NP
is given by:
Encapsulation efficiency (%) =
Amount of curcumin in PLGA NP
Amount of curcumin used in the synthesis
× 100. (1)
Stability of PLGA NP encapsulated curcumin
Kinetic UV-visible absorption spectra (300 to 800 nm) of the Cur-PLGA NPs were recorded
with a UV-1800 UV-VIS spectrophotometer (Shimadzu, Japan). To demonstrate the aque-
ous stability of the curcumin in PLGA NPs, UV-visible spectra of Cur-PLGA NP solution
containing approximately 15 µm of curcumin (A420 nm ≈ 1) were collected at 15-min intervals
for 12 h, 24 h and 48 h at 37 ◦C. The concentration of curcumin in the Cur-PLGA NP solution
was determined using UV-visible spectroscopy and adjusted with addition of Milli-Q water.
To demonstrate the rapid degradation of native curcumin in water, UV-visible spectra of
curcumin in water were collected at 15-min intervals for 6 h at 37 ◦C. To prepare curcumin
in an aqueous solution, an aliquot of 2mgmL−1 curcumin in acetone stock was added to
Milli-Q water to yield a solution with A420 nm ≈ 1. All UV-visible experiments were done in
triplicates and results were reported as the mean with the standard deviation of the mean
as error.
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Fluorescence spectroscopy of Cur-PLGA NP
Fluorescence emission spectrum of the Cur-PLGA NP (430 to 650 nm) was recorded with
a Fluorescence Spectrometer F-7000 (Hitachi, Japan). The absorbance of Cur-PLGA NP
at 420 nm was adjusted to 0.1 for the fluorescence measurement to minimize the inner filter
effect. The excitation used was 420 nm with a 5 nm slit width, while the emission slit width
was set at 2.5 nm. The reported fluorescence emission spectrum was the average of three
measurements.
Cur-PLGA NP cellular uptake
The qualitative cellular uptake studies involved imaging leukemia Jurkat and NIH3T3 fibrob-
last cell lines with both the native curcumin and the Cur-PLGA NP treatments. Experi-
ments were repeated three times to ensure the reproducibility. The synthesized Cur-PLGA
NP and blank PLGA NP solutions were further concentrated to minimize the hypotonic
stress to cells. The concentration of curcumin in the Cur-PLGA NP solution was deter-
mined using UV-visible spectroscopy and adjusted with addition of Milli-Q water. The final
dosage volume is less than 10% of the total volume. Cells were washed with 0.5mL of
PBS three times so that only intracellular curcumin was detected before fixation using 4%
paraformaldehyde and staining of cell nucleus with Hoechst 33258 solution (Sigma Aldrich,
Japan). The fluorescence images were captured by a Nikon Eclipse Ti-E Spinning Disk (An-
dor, Japan) confocal microscope and controlled with Andor iQ3 Live Cell Imaging software
using the GFP and DAPI channels. The fluorescence intensity of curcumin in cells were
measured with a flow cytometer (Accuri C6, Becton Dickinson Biosciences, USA). The blue
fluorescence from Hoechst 33258 and the green fluorescence from curcumin were analyzed
using the 533/30 and 585/40 filter, respectively. The flow cytometery data were analyzed
with FlowJo 10.4.2 (FlowJo LLC, USA).
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Cell viability
Cells were seeded at 1× 104 cells/well in 24-well plates (Thermo Scientific, USA) with various
concentrations of Cur-PLGA NP and then incubated for 1 to 3 days. Experiments were
repeated three times to ensure the reproducibility. The synthesized Cur-PLGA NP and
blank PLGA NP solutions were further concentrated and the concentration of curcumin
was determined using UV-visible spectroscopy and adjusted with addition of Milli-Q water.
The final dosage volume was less than 10% of the total volume and the additional water
did not induce cell death. To assess the cell viability, cells were stained using the MuseTM
Count and Viability Assay Kit and analyzed using a MuseTM Cell Analyzer according to
manufacturer’s instructions (EMD Millipore, Japan). Both viable and non-viable cells were
differentially stained based on their permeability to two DNA-binding dyes in the reagent
solution. The cell viability calculations were performed automatically using the MuseTM
Count and Viability Software Module. The Cur-PLGA NP dose-response of Jurkat cells
was investigated with various concentrations of curcumin in the Cur-PLGA NP solution and
analyzed with OriginPro 2016 software (OriginLab, USA).
RESULTS AND DISCUSSION
Microfluidic synthesis of Cur-PLGA NP
A cross slot microfluidic device was fabricated with PDMS bonded to glass for the nano-
precipitation by hydrodynamic flow focusing as described in the Introduction. The cured
PDMS was extracted in a series of organic solvents and oxidized using plasma to generate a
hydrophillic surface at the channel wall.28 It has been found that the hydrophilic surface is
essential in the synthesis of Cur-PLGA NP as the interaction between nanoparticles and the
wall can be significantly reduced to minimize the aggregation inside the microfluidic channel.
The uncross-linked low molecular weight oligomers in the PDMS are removed during solvent
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extraction and a layer of SiO2 is generated by air plasma resulting in a stable hydrophilic
surface of the channel wall.28 Milli-Q water was introduced as the continuous phase for all
nanoparticle synthesis as shown in Figure 2a. For the synthesis of bare PLGA NP, a stock so-
lution containing 0.5mgmL−1 PLGA in acetone were introduced into the device as dispersed
phase. For the synthesis of Cur-PLGA NP, a stock solution containing 0.5mgmL−1 PLGA
and 0.05mgmL−1 curcumin (1:10 curcumin:PLGA by weight) in acetone were introduced
into the device as dispersed phase (Figure 2a). Both bare PLGA NP and curcumin encapsu-
lated Cur-PLGA NP were successfully synthesized with the fabricated cross slot microfluidic
device.
The green fluorescence shown in Figure 2a arises from the emission of curcumin. Cur-
cumin exhibits green fluorescence in organic solvents, however, it is non-fluorescent in water
due to efficient fluorescence quenching by water molecules.32 At low flow rates (i.e., low
Reynolds numbers), due to the small dimension of the microchannels, the dispersed phase
(curcumin and PLGA in acetone) is squeezed into a narrow focused stream by the two con-
tinuous streams (water) as shown in Figure 2a. This significant reduction of the width to
approximately 0.6 µm of dispersed phase enables rapid mixing as the diffusion length scale
is shortened.21 A controlled rapid mixing of the dispersed and continuous phase is achieved
for the nanoprecipitation due to solvent exchange of the two phases as discussed before.
Effect of flow rate ratio (Rflow rate)
According to the classical nucleation theory, supersaturation is very important because it
determines the nucleation rate, which also depends on the diffusion of curcumin and PLGA
molecules.20 Therefore, rapid mixing of the solvent and the non-solvent phases results in fast
nucleation and formation of smaller nuclei.20 As a result, microfluidics serves as a powerful
platform for the nanoprecipitation via solvent exchange because microfluidics enables rapid
and controlled mixing of the dispersed and continuous phase.21,24,25 It has been shown that
the width of the focused stream is dependent on the flow rate ratios (Rflow rate), which is
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Figure 2: Nanoprecipitation of Cur-PLGA NP by hydrodynamic flow focusing. (a) Fluo-
rescence image of Cur-PLGA NP by nanoprecipitation at the hydrodynamic flow focusing
region inside a microfluidic device with 420 nm excitation. The flow rate of water and acetone
are 20 µLmin−1 and 1 µLmin−1, respectively. AFM images of the microfluidic synthesized
(b) bare PLGA NP and (c) Cur-PLGA NP on mica substrate with a scan area of 800× 800
nm and the red circles highlight nanoparticle aggregates. TEM images of the (d) bare PLGA
NP and (e) Cur-PLGA NP showing spherical shaped nanoparticles.
the flow rate ratio between the dispersed and continuous phases. The smaller the Rflow rate,
decreases the width of the focused stream, which shortened the diffusion length scale, and
hence reduce the time scale for solvent exchange.21 In order to generate nanoparticle with
monodispersity, mixing time must be less than the aggregation time (on the order of ms).21
The mixing time (τmix) for solvent exchange can be estimated from Rflow rate using the fol-
lowing relationship21
τmix ≈ w
2
9D
1
(1 + 1
Rflow rate
)2
, (2)
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where D is the diffusivity of the solvent and w is the channel width. Equation (2) is an
approximation of the timescale for mixing in a 2D hydrodynamic flow focusing configuration,
assuming that the velocity of the focused stream is equal to the centerline velocity of the
continuous stream.21 The flow rates of continuous and dispersed phase were controlled using
syringe pumps and the flow rate of continuous phase was maintained at 20 µLmin−1 while
the dispersed phase was varied from 0.5 to 2.5 µLmin−1. The predicted mixing times by
Equation (2) are in the range of 0.03 to 0.55ms (Table 1). Further discussion on the effect
of Rflow rate on the particle size and size distribution are detailed in the Results Section .
Selection of the PLGA concentrations
It has been reported that polymer concentration in the initial dispersed phase can impact the
size of nanoparticles. Diluting the polymer solution leads to a decrease in the particle size and
polydispersity.21,33 This concentration effect has been related to the specific polymer-polymer
interactions, which arises when the polymer concentration is above the critical chain overlap-
ping concentration (C∗).33 A 0.5mgmL−1 PLGA in an acetone solution (the concentration
used in this study) is well below the C∗ of PLGA which is 42.4mgmL−1.34 At this concen-
tration, there is no specific polymer-polymer interactions and the PLGA polymer chains are
well solvated by acetone, resulting in independent PLGA chains. Thus, water penetrates
in between PLGA chains and promotes small isolated PLGA clusters during nucleation af-
ter solvent exchange. Previous study has also shown that the ability to stabilize curcumin
with PLGA NP is dependent on the concentration ratio between the curcumin to PLGA
used in the synthesis. There is a 3 times reduction in the rate of degradation of curcumin
for a 1:10 ratio compared to 1:5 curcumin:PLGA ratio by weight.6 This enhancement has
been attributed to a more efficient encapsulation of curcumin and leads to segregation cur-
cumin from water molecules, which suppresses the hydrolysis of curcumin.6 Based on these
preliminary results, a solution of 1:10 Cur:PLGA in acetone is used to suppress curcumin
degradation in all the microfluidic Cur-PLGA NP synthesis in this work.
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Selection of the solvent for PLGA
The choice of the solvent is important for the nanoprecipitation of Cur-PLGA NP. Generally,
acetone is the most common solvent for the nanoprecipitation of PLGA NP as it is readily
miscible with water, easily removed by evaporation and a theta solvent in which PLGA
are considered to behave like ideal chains. The interaction between acetone and PLGA
is predicted using Bagley’s two-dimensional graph shown in the Supporting Information
(Figure S.1).35 A polymer is expected to be soluble in a solvent if the solvent is within the
solubility sphere of the polymer and the radius of the solubility sphere is also known as the
interaction radius and it is 7.5 for the PLGA used in this study.36 As shown in Bagley’s two-
dimensional graph (Supporting Information Figure S.1), acetone is located in the solubility
circle of PLGA while water is far away from it, which indicates that acetone is a theta solvent
but water is a non-solvent for PLGA.
Characterizations of Cur-PLGA NP
Particle size and size distribution
To confirm the formation of nanoparticles, reaction mixture was collected from the outlet
stream of the microfluidic cross slot device and drop-casted on a mica substrate before imaged
with atomic force microscopy (AFM). The AFM images of bare PLGA NP and Cur-PLGA
NP synthesized with Rflow rate = 0.05 are shown in Figure 2b and c. There are some degree
of aggregations observed in the dried Cur-PLGA NP sample, which is due to evaporation
of the solvent. The identified aggregates (as indicated by the red circles in Figure 2 as an
example) are considered as outliers in the size analysis and the diameter of bare PLGA NP
and Cur-PLGA NP are 26± 3 nm and 24± 6 nm, respectively, with a height of less than
600 pm. The flattening of Cur-PLGA NP can be attributed to the dehydration and their
strong interaction with the substrate when particles are adsorbed on the mica substrate
during the AFM sample preparation. Furthermore, the morphology of the bare PLGA NP
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and Cur-PLGA NP are investigated with TEM, see TEM images shown in Figure 2(d,e). The
microfluidic synthesized bare PLGA NP and Cur-PLGA NP both exhibit spherical shapes
with smooth surfaces.
Table 1: Summary of particle diameter and Zeta potential of the Cur-PLGA NP at various
flow rate ratios (Rflow rate) resulting in different mixing time (τmix).
Rflow rate
τmix Diametera PDIa,b Zeta Potential
a Encapsulation Efficiencya
(ms) (nm) (mV) (%)
0.025 0.03 32± 4 0.13± 0.06 −44± 1 55± 2
0.05 0.10 33± 4 0.14± 0.02 −58± 3 59± 5
0.05 c 0.10 49± 12 0.15± 0.02 −44± 1 NA
0.05 d 0.10 31± 2 0.15± 0.02 −59± 5 NA
0.05 e 0.10 29± 2 0.15± 0.02 −43± 3 NA
0.075 0.22 46± 7 0.14± 0.01 −44± 1 67± 2
0.1 0.37 52± 3 0.11± 0.01 −47± 3 57± 4
0.125 0.55 71± 4 0.12± 0.01 −58± 2 65± 3
aThe reported values are the mean value of three independent experiments and the error
values are the standard deviation of the mean.
bPDI is derived from the second and third cumulant.30 The PDI of less than 0.2 indicate
monodispersity.
cThe reported values are for blank PLGA NP.
dThe reported values are for Cur-PLGA NP after 24 hours.
eThe reported values are for Cur-PLGA NP after 48 hours.
Next, the hydrodynamic diameters of Cur-PLGA NP synthesized at various flow rates and
flow rate ratios Rflow rate were determined from DLS measurements, summarized in Table 1
and the particle size distributions are shown in Figure 3. The rapid mixing by hydrodynamic
flow focusing is responsible for the shortened τmix for solvent exchange.21 For the Rflow rate
used in this study, the estimated τmix (see Equation (2)) ranges from 0.03 to 0.55ms. The
focused stream becomes narrower when the Rflow rate decreased and mixing is enhanced be-
tween the continuous and dispersed phase by significantly reduced τmix.21 As a result, a
more uniform nucleation is expected and leads to an improved size distribution. Overall,
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the Cur-PLGA NP have diameters of less than 100 nm and PDI less than 0.2 for various
Rflow rate studied. Furthermore, there is little aggregation observed over a period of 2 days
which demonstrates the excellent colloidal stability of these Cur-PLGA NP. The microflu-
idic synthesized Cur-PLGA NP (30–70 nm in diameter) exhibit smaller particle size than
those synthesized using conventional nanoprecipitation (68± 16 nm) reported previously.6
The slight discrepancy in the particle size between the AFM and DLS results is attributable
to the fact that the hydrodynamic diameter of Cur-PLGA NP in solution is measured by
DLS, which tends to overestimate the particle size.37
Figure 3: Particle size distribution of Cur-PLGA NP synthesized at various Rflow rate. The
flow rate of the continuous phase was maintained at 20 µLmin−1 and the dispersed phase
was varied from 0.5 to 2.5 µLmin−1. Inset shows the particle size dependence on Rflow rate
where results are the mean of three independent experiments and the errors are standard
deviation of the mean.
In addition to the effect on particle size, the Rflow rate influences the monodispersity of
the synthesized Cur-PLGA NP. Our Cur-PLGA NP are monodispersed as PDI less than
0.2 (Table 1) indicates a homogenous particle population, while a PDI value greater than
0.3 indicates heterogeneity. However, it is important to note that the PDI value from the
cummulant method does not distinguish between a broad and a bimodal distribution.30 In-
stead of the cummulant method, CONTIN method is used to investigate the particle size
distribution as shown in Figure 3.31 A decrease in the particle size is observed with decreas-
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ing Rflow rate, the size distribution of Cur-PLGA NP synthesized with a Rflow rate of 0.025 is
narrower than those with a Rflow rate of 0.125 (Figure 3). For the formation of NP with low
PDI, rapid mixing is essential for homogeneous supersaturation of solution, which is achieved
with a short mixing time (as summarized in Table 1) to ensure uniform nucleation.20,21 A de-
crease in the particle diameter is accompanied by improved size distribution with decreasing
Rflow rate (Figure 3), which is in good agreement with a previous study on microfluidic as-
sisted synthesis of polymer NP.21 Furthermore, the size distribution dependency on Rflow rate
suggests that the rate of particle growth is slower than the τmix.21 Since our Cur-PLGA NP
synthesized using nanoprecipitation principle in a microfluidic device yield monodispersed
particles with particle diameters less than 100 nm, Cur-PLGA NP are expected to improve
the bioavailability of curcumin and the subsequent accumulation in tumors due to the EPR
effect.
Colloidal stability
To examine the colloidal stability of the Cur-PLGA NP, its zeta potentials are measured
by an electrophoretic light scattering spectrophotometer (ELZS-2000). The Cur-PLGA NP
exhibit negative zeta potentials ranging from −44 to −58mV (Table 1) and it is in good
agreement with previous studies of Cur-PLGA NP synthesized by conventional nanoprecip-
itation method.1,6 The negatively charged surface of the Cur-PLGA NP indicates excellent
colloidal stability, as the electrostatic repulsive interaction is greater than the attractive van
der Waals interaction among Cur-PLGA NP, resulting a stable aqueous suspension. Note
that there is no observable aggregation within the time of measurement (Supporting Infor-
mation Figure S.3).
Stability of the PLGA NP encapsulated curcumin
Next, we investigate the stability of Cur-PLGA NP with UV-visible absorption spectroscopy
(Shimadzu UV-1800). Figure 4 shows the UV-visible spectra of Cur-PLGA NP over time.
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We observe a strong absorption in the UV-visible spectral region with absorption maximum
at 422 nm and two shoulders around 350 and 450 nm, as shown in Figure 4 (arrows). The
absorption band observed at 422 nm is attributed to the pi−pi∗ transition of curcumin as
PLGA are optically transparent in the visible spectrum.6,38 In addition to the absorption
peaks, a shoulder in the absorption spectrum is also observed at 450 nm which is absent in
the absorption spectrum curcumin in an aqueous environment16 (Figure 4). The UV-visible
absorption spectrum of curcumin in PLGA NP agrees well with curcumin in dimethylfor-
mamide (DMF), which indicates that curcumin is likely to be located in an environment
that is similar to DMF.32 Therefore, the enhanced stability of curcumin encapsulated in-
side PLGA NP compared to native curcumin is due to its segregation from the aqueous
environment. As water molecules are absent in the hydrophobic regions of the PLGA NP,
the suppression of hydrolysis of curcumin, which is the major pathway of degradation of
curcumin, can be achieved using PLGA NP.
Figure 4: Kinetic UV-visible absorption spectra of Cur-PLGA NP (Rflow rate=0.05) at 37 ◦C
with inset showing the decrease of absorbance at 422 nm over time of Cur-PLGA NP (circles),
fitted with the pseudo-zero-order kinetic model (solid line), and native curcumin in water
(crosses).
As the absorption maximum at 422 nm is due to the presence of curcumin in PLGA
NP, the stability of native curcumin in water and curcumin encapsulated in PLGA NP was
determined by monitoring the change in absorbance at this wavelength over time (Figure
4 inset). The striking difference between the degradation of native curcumin and Cur-
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PLGA NP demonstrated the excellent stabilization of curcumin encapsulated by PLGA NP.
The decrease in absorbance signifies a depletion of curcumin which is attributed to the
degradation of curcumin and the slow decay of Cur-PLGA NP is fitted to a pseudo-zero-
order kinetic model (represented as a solid line in the inset of Figure 4). The pseudo-zero-
order kinetics has been observed in the curcumin degradation,39 while the rate of curcumin
degradation is 1.1± 0.4%h−1 when encapsulated in our microfluidic synthesized PLGA NP.
The PLGA NP encapsulated curcumin has an extended half life of approximately 2 days
compared to ∼30min for the native curcumin in water (Figure 4 inset) as expected.15,16 It
has been proposed that curcumin is encapsulated in the hydrophobic regions of PLGA NP,
which results in curcumin segregated from water and suppresses hydrolysis of curcumin.6
The encapsulation efficiency is calculated according to Equation 1 and the values are sum-
marized in Table 1. Overall, the encapsulation efficiency of our Cur-PLGA NP is around
55 to 67%. Our Cur-PLGA NP has a moderate encapsulation efficiency of curcumin com-
pared to other curcumin nanoparticle systems with an encapsulation efficiency ranges from
50 to 90%.10,40,41 It has been shown that the encapsulation efficiency is dependent on the
present stabilizer as the addition of stabilizer enhances the swelling of PLGA NP to encap-
sulate curcumin.41 Analysis on the Hansen solubility parameters of curcumin and PLGA
have shown that curcumin is able to be encapsulated within the PLGA NP by forming a
homogeneous mixture with the PLGA NP.6 As a result, curcumin is expected to be uni-
formly distributed inside PLGA NP resulting in segregation from the aqueous environment
and exhibits stability inside PLGA NP. Similar to a previous study,6 the volume of Cur-
PLGA NP (Rflow rate = 0.05) was calculated based on the average diameter of 33 nm (Table
1) and the average number of curcumin per nanoparticle was estimated to be 7.6× 103.
Our microfluidic synthesized PLGA NP exhibit effective encapsulation and stabilization of
curcumin, therefore, it is expected that Cur-PLGA NP has the potential as delivery system
for curcumin and improves the bioavailability of curcumin.
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Cellular uptake of curcumin
We show proof of concept studies of using the microfluidic synthesized Cur-PLGA NP as
nontoxic and effective delivery system for curcumin without perturbing its medicinal prop-
erties. First, we assessed the ability of the synthesized Cur-PLGA NP delivering curcumin
to leukemia Jurkat and NIH3T3 fibroblast cell lines. The amount of cellular uptake were
monitored using confocal fluorescence microscopy. Figure 5 shows the fluorescence images of
leukemia Jurkat cells incubated with 6 µm native curcumin and Cur-PLGA NP containing
6 µm of curcumin for 4 hours and 2 days. An aliquot of 1mgmL−1 curcumin in acetone stock
solution was used to yield 6 µm of curcumin. The blue fluorescence is due to the nucleus
Hoechst stain with 350 nm excitation and the fluorescence intensity is constant across the
media control and various treatments. The microfluidic synthesized Cur-PLGA NP exhibit
green fluorescence emission (maximum at 500 nm) upon excitation with 420 nm (Supporting
Information Figure S.4). This green fluorescence emission is in excellent agreement with
previous studies and it is attributed to the emission of curcumin encapsulated in PLGA
NP.6,32 Therefore, the green fluorescence observed with confocal microscopy is attributed to
the combination of intrinsic cell fluorescence and curcumin fluorescence for cells with cur-
cumin treatments. Cellular uptake of Cur-PLGA NP by NIH3T3 fibroblast cells were also
monitored and similar observations were made (Supporting Information Figure S.5).
The mean green fluorescence intensity was determined and compared for various treat-
ments with leukemia Jurkat and NIH3T3 fibroblast cells as shown in Figure 6. We observed
no specificity in the curcumin delivery as the fluorescence intensity increased in both leukemia
Jurkat and NIH3T3 fibroblast cell lines treated with Cur-PLGA NP compared to the media
control (without curcumin treatment). The fluorescence increases after 4 hours of incuba-
tion (Figure 6, blue bars) in both leukemia Jurkat and NIH3T3 cell lines. This significant
increase in the fluorescence intensity inside leukemia Jurkat and NIH3T3 fibroblast cell lines
with Cur-PLGA NP or native curcumin compared to the media control implies that there is
a higher cellular concentration of curcumin. The overall fluorescence intensity in leukemia
20
Figure 5: Confocal fluorescence image of Jurkat cells in the media control, treated with 6 µm
of native curcumin and with the equivalent curcumin concentration of Cur-PLGA NP for 4 h
and 2 days. Images were taken with 20x magnification. Rows from top to bottom: curcumin
fluorescence (excitation at 420 nm), cell nuclei stained with Hoechst (excitation at 350 nm)
and overlaid image of curcumin and Hoechst fluorescence.
Jurkat cell is similar to the NIH3T3 fibroblast cell with the same treatments of native cur-
cumin or Cur-PLGA-NP. As the cellular autofluorescence of NIH3T3 fibroblast is higher
than leukemia Jurkat cell, the fluorescence intensity increase is greater in leukemia Jurkat
cell than NIH3T3 fibroblast. This increase in the fluorescence intensity (blue bars, Figure
6) has been ascribed to the hydrophobic environments of tumor cells.42 These results have
demonstrated that the PLGA NP do not alter the cell uptake of curcumin by both leukemia
Jurkat and NIH3T3 fibroblast cells.
The overall fluorescence intensity of cells with Cur-PLGA NP and native curcumin treat-
ments decreases after 2 days (Figure 6, red bars) indicating that there are less curcumin
present in cells. Furthermore, the decrease in fluorescence intensity for both cell lines with
Cur-PLGA NP treatment is less than those treated with native curcumin. The higher fluores-
cence intensity indicates there are more curcumin present in cells and this can be attributed
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to the stabilization of curcumin by PLGA NP (Figure 4). Interestingly, there are more cur-
cumin uptake in Jurkat cell with 4 hours of native curcumin incubation than Cur-PLGA
NP (Figure 6 (left, blue bars)), however, there are less native curcumin than Cur-PLGA NP
after 2 days of incubation (Figure 6 (left, red bars)). Overall, Cur-PLGA NP is a better
delivery system for curcumin as the amount of cellular curcumin deliver by Cur-PLGA NP
is higher than native curcumin in both Jurkat and NIH3T3 fibroblast cell lines (Figure 6,
red bars).
Figure 6: Cellular uptake of curcumin and Cur-PLGA NP by leukemia Jurkat (right) and
NIH3T3 fibroblast (left) cells after 4 h (blue bars) and 2 days (red bars) of incubation in
triplicates. The results shown are the median fluorescence intensity and the errors are
coefficient of variation of the median.
Cell viability with curcumin treatment
We next investigate the cell viability of leukemia Jurkat and NIH3T3 fibroblast cell lines
with Cur-PLGA NP treatment. The effect of Cur-PLGA NP on the viability of leukemia
Bcl-2 (S70A) Jurkat and NIH3T3 fibroblast cells were evaluated and the results are shown
in Figure 7. In comparison with all control treatments, cell viability decreased in Jurkat cell
with both native curcumin and the Cur-PLGA NP treatment. Cell viability have dropped
to 74% and 56% for native curcumin and the Cur-PLGA NP treatments (yellow and white
bars respectively in Figure 7), despite of its resistance to apoptosis via phosphorylation of
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Bcl-2 proteins at serine 70.43 It has been reported that the curcumin-induced Jurkat cells
apoptosis is independent of the level of Bcl-2 protein.44 Additionally, Jurkat cells apoptosis
is linked to the elevated level of cellular glutathione induced by curcumin.45
Since the cell uptake results confirmed that there are same cellular concentration of cur-
cumin in Jurkat by native curcumin and the Cur-PLGA NP treatments (Figure 6), the
difference in the cell viability of Jurkat cells is obviously not caused by the cellular concen-
tration of curcumin alone, but also related to the stability of curcumin. Although similar
cell uptake trend of curcumin is observed in NIH3T3 fibroblast cells, there is no decrease on
the cell viability for all the treatments (Figure 7), verifying that native curcumin and the
Cur-PLGA NP are nontoxic to NIH3T3 fibroblast cells, consistent with previous reports at
comparable curcumin dosages.3,46 For example, it has been reported that there is no observ-
able effect on NIH3T3 cells viability up to 20µm dosage of curcumin, while another study
has shown there is no effect on the growth of NIH3T3 cell up to 1mm of curcumin.46
Figure 7: Cell viability assays on Jurkat (left) and NIH3T3 fibroblast (right) cells treated
with 5 µm of curcumin; and with the equivalent curcumin concentration of Cur-PLGA NP,
along with cell culture media, water, acetone and blank PLGA NP control experiments for
2 days. The results shown are the mean of triplicates and the errors are standard deviation
of the mean.
To evaluate the effect of Cur-PLGA NP against Jurkat cell, we also conducted dosage
dependent cytotoxicity of Cur-PLGA NP. Jurkat cells exhibit a dosage response with the
concentration of curcumin in Cur-PLGA NP over a period of 2 day incubation after a single
dosage. An increase in the cell death is observed with increasing curcumin concentration in
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the Cur-PLGA NP solution as shown in Figure 8. The 50% maximal inhibitory response
(IC50) is about 5.3 µm, which is calculated from the sigmoidal fit (Figure 8, solid curve).
Our results are comparable to other studies, which have shown that the IC50 of curcumin is
between 3 to 14 µm for Jurkat cells.47,48
Figure 8: Dosage response of Jurkat cells to Cur-PLGA NP between 1 to 10 µm of curcumin
over a period of 2 days after a single dosage. Results are presented as the mean of three
independent experiments and the reported error is the standard deviation of the mean. The
IC50 is about 5.3 µm calculated from a sigmoidal fitting (solid curve). Note that x-axis is the
log of curcumin concentration in the Cur-PLGA NP determined by UV-visible spectroscopy.
CONCLUSIONS
The ability to control particle size of nanoparticles is critical for its biodistribution and cel-
lular uptake. A size tunable synthesis of Cur-PLGA NP using a microfluidic hydrodynamic
flow focusing platform has been demonstrated. The resulting Cur-PLGA NP are less than
100 nm in diameter with a narrow size distribution and excellent colloidal stability. Our Cur-
PLGA NP significantly inhibit the degradation of curcumin with the rate of degradation of
1.1± 0.4%h−1. Our microfluidic synthesized Cur-PLGA NP is a nontoxic and effective de-
livery system for curcumin, in particular, it enhances anti-cancer activity of curcumin against
leukemia Jurkat cells compared to native curcumin. Our findings motivate the application of
microfluidic technologies for the synthesis of polymer nanoparticle for effective drug delivery.
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